Current Report Filing (8-k)
20 July 2022 - 8:01PM
Edgar (US Regulatory)
0001728328
false
A1
0001728328
2022-07-15
2022-07-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 15, 2022
INMED PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)
British Columbia |
|
001-39685 |
|
98-1428279 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
Vancouver, B.C.
Canada |
|
V6C 1B4 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Company’s telephone number, including
area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Shares, no par value |
|
INM |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On July 18, 2022, InMed Pharmaceuticals
Inc. (the “Company”) issued a press release to announce that it has appointed Mr. Michael Woudenberg as the Company’s
Chief Operating Officer effective July 15, 2022 (the “Effective Date”). He was previously Senior Vice President of Chemistry,
Manufacturing and Controls. Mr. Woudenberg has been an integral part of the executive team for the last four years, supporting multiple
functions within the Company. Prior to joining the Company, Mr. Woudenberg had over 20 years of successful drug development, process engineering,
GMP manufacturing and general management experience at all levels of various companies, including, most recently as managing director
of Phyton Biotech from March 2016 to October 2018.
In connection with his appointment, Mr. Woudenberg
and the Company entered into an employment agreement dated July 15, 2022 (the “Employment Agreement”), pursuant to which he
will receive an annual base salary of C$300,000. He is also eligible to be considered for an annual discretionary bonus, targeted at 40%
of his base salary, which will be subject to the approval of the Board and the compensation committee of the Company. The Employment Agreement
contains certain restrictive covenants that apply during and after his employment, including confidentiality, non-competition and non-solicitation
agreements.
There is no family relationship between Mr. Woudenberg
and the Company. There is no related party transactions with Mr. Woudenberg required to be disclosed as required by Item 404(a) of Regulations
S-K.
Item 7.01 | Regulation FD Disclosure. |
On July 18, 2022, the Company issued a press release
announcing the appointment of Mr. Woudenberg. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein
by reference.
The information set forth in this Item 7.01, including
Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth
in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits:
The following exhibit shall be deemed to be furnished, and not filed:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMED PHARMACEUTICALS INC. |
|
|
|
Date: July 19, 2022 |
By: |
/s/ Brenda Edwards |
|
|
Brenda Edwards |
|
|
Interim Chief Financial Officer |
2
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2024 to May 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From May 2023 to May 2024